GRTX · As filed with the SEC
Galera Therapeutics cash flow statement, by quarter
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Operating activities: | ||||
| Net loss | (1,606,000) | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | — | 0† | 0† | 0† |
| Share-based compensation expense | 78,000 | — | — | — |
| Write-off of acquired intangible asset | — | 0† | — | — |
| Write-off of goodwill | — | 0† | — | — |
| Change in fair value of warrants | 0 | — | — | — |
| Gain on disposal of property and equipment | — | 0† | — | — |
| Deferred tax benefit | — | 0† | — | — |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 157,000 | — | — | — |
| Other assets | 0 | — | — | — |
| Accounts payable | 434,000 | — | — | — |
| Accrued expense | 62,000 | — | — | — |
| Other liabilities | — | 0† | 0† | 0† |
| Cash used in operating activities | (875,000) | — | — | — |
| Proceeds from sale of property and equipment | — | 0† | — | — |
| Cash provided by investing activities | — | 3,500,000† | — | — |
| Financing activities: | ||||
| Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs | 0 | — | — | — |
| Cash provided by financing activities | 0 | — | — | — |
| Net decrease in cash and cash equivalents | (875,000) | — | — | — |
| Cash and cash equivalents at beginning of period | 6,375,000 | 4,473,000 | 5,230,000 | 6,686,000 |
| Cash and cash equivalents at end of period | 5,500,000 | 6,375,000 | 4,473,000 | 5,230,000 |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Accretion (amortization) of redeemable convertible preferred stock to redemption value | 1,718,000 | — | — | — |
| Reclassification of warrant liability to additional paid-in capital | 0 | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.